AtriCure

AtriCure, Inc. (NASDAQ: ATRC) was founded in 2000 and is headquartered in Mason, Ohio. The company develops, manufactures, and sells surgical ablation devices for cardiac tissue and systems to medical institutions in the United States and internationally. As a leading provider of innovative technologies for treating atrial fibrillation (Afib) and related conditions, electrophysiologists and cardiothoracic surgeons worldwide rely on AtriCure to deliver first-class solutions, even for the most complex cases. AtriCure’s Isolator Synergy™ Ablation System is the first and only FDA-approved medical device for the long-term treatment of persistent Afib, and its AtriClip Left Atrial Appendage (LAA) Exclusion System is the most widely used LAA management device globally, now expanding into pain management therapies. The company invests in innovation, clinical science, and education with a commitment to improving patients’ lives worldwide. AtriCure offers the Isolator Synergy and Isolator Synergy Access clamps for treating persistent and long-standing persistent atrial fibrillation associated with other open-heart surgeries; the EPi-Sense Guided Coagulation System for tissue coagulation; and the COBRA Fusion Surgical Ablation System, which combines bipolar temperature-controlled radiofrequency energy with monopolar energy.